Brief: Tetra Bio-Pharma Provides Update On Its Hepatocellular Carcinoma Drug

Tetra Bio Pharma

10/12/2019 13:17

Dec 10 (Reuters) - Tetra Bio Pharma Inc  TBP.V :
    * TETRA BIO-PHARMA PROVIDES UPDATE ON ITS HEPATOCELLULAR
CARCINOMA
DRUG HCC011
    * TETRA BIO PHARMA INC - TETRA TO PURSUE 505(B)(2) NDA
PATHWAY AND
EXPEDITED REVIEW FOR ITS ORPHAN DRUG CANDIDATE HCC011
    * TETRA BIO PHARMA - ORPHAN DRUG DESIGNATION QUALIFIES CO
FOR
CERTAIN INCENTIVES AND BENEFITS, INCLUDING A 50% TAX CREDIT UPON
APPROVAL OF HCC011
    * TETRA BIO PHARMA - WILL BE REQUESTING A MEETING WITH U.S.
FDA TO
DISCUSS DRUG DEVELOPMENT PROGRAM FOR ITS ORPHAN DRUG CANDIDATE
HCC011

Source text for Eikon:  ID:nGNX8xrX9h 
Further company coverage:  TBP.V 

 ((Reuters.Briefs@thomsonreuters.com;))